Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells

被引:126
作者
Gonzalez-Rey, E
Chorny, A
Fernandez-Martin, A
Ganea, D
Delgado, M
机构
[1] CSIC, Inst Parasitol & Biomed, Granada 18100, Spain
[2] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA
关键词
D O I
10.1182/blood-2005-11-4497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Induction of antigen-specific tolerance is critical for autoimmunity prevention and immune tolerance maintenance. In addition to their classical role as sentinels of the immune response, dendritic cells (DCs) play important roles in maintaining peripheral tolerance through the induction/activation of regulatory T(T-reg) cells. The possibility of generating tolerogenic DCs opens new therapeutic perspectives in autoimmune/inflammatory diseases. Characterizing endogenous factors that contribute to the development of tolerogenic DCs is highly relevant. We here report that the immunosuppressive neuropeptide vasoactive intestinal peptide (VIP) induces the generation of human tolerogenic DCs with the capacity to generate CD4 and CD8 Treg cells from their respective naive subsets. The presence of VIP during the early stages of DC differentiation from blood monocytes generates a population of IL-10-producing DCs unable to fully mature after the effects of inflammatory stimuli. CD4 T-reg cells generated with VIP-differentiated DCs resemble the previously described TO cells in terms of phenotype and cytokine profile. CD8 T-reg cells generated with tolerogenic VIP DCs have increased numbers of IL-10-producing CD8(+)CD28(-)CTLA4(+) T cells. CD4 and CD8 T-reg cells primarily suppress antigen-specific T(H)1-mediated responses. Therefore, the possibility of generating or expanding ex vivo tolerogenic DCVIPs opens new therapeutic perspectives for treating autoimmune diseases and graft-versus-host disease after allogeneic transplantation in humans.
引用
收藏
页码:3632 / 3638
页数:7
相关论文
共 40 条
[1]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[2]   Neuropilin-1: a surface marker of regulatory T cells [J].
Bruder, D ;
Probst-Kepper, M ;
Westendorf, AM ;
Geffers, R ;
Beissert, S ;
Loser, K ;
von Boehmer, H ;
Buer, J ;
Hansen, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) :623-630
[3]   Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders [J].
Chorny, A ;
Gonzalez-Rey, E ;
Fernandez-Martin, A ;
Pozo, D ;
Ganea, D ;
Delgado, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) :13562-13567
[4]  
CHORNY A, 2006, BLOOD 0117, DOI DOI 10.1182/BLOOD-2005-11-4495
[5]   CD8+CD28- T suppressor cells represent a distinct subset in a heterogeneous population [J].
Colovai, AI ;
Ciubotariu, R ;
Liu, Z ;
Cortesini, R ;
Suciu-Foca, N .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :104-107
[6]   The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells [J].
Delgado, M ;
Gonzalez-Rey, E ;
Ganea, D .
JOURNAL OF IMMUNOLOGY, 2005, 175 (11) :7311-7324
[7]   VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells [J].
Delgado, M ;
Reduta, A ;
Sharma, V ;
Ganea, D .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (06) :1122-1130
[8]   The significance of vasoactive intestinal peptide in immunomodulation [J].
Delgado, M ;
Pozo, D ;
Ganea, D .
PHARMACOLOGICAL REVIEWS, 2004, 56 (02) :249-290
[9]   Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans [J].
Dhodapkar, MV ;
Steinman, RM .
BLOOD, 2002, 100 (01) :174-177
[10]   The role of CD40 in peripheral T cell tolerance and immunity [J].
Diehl, L ;
Den Boer, AT ;
van der Voort, EIH ;
Melief, CJM ;
Offringa, R ;
Toes, REM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2000, 78 (07) :363-371